A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F
暂无分享,去创建一个
K. Ohashi | M. Hidaka | S. Fuji | A. Takami | S. Kurosawa | T. Fukuda | K. Hatanaka | S. Yano | T. Yamashita | H. Nakamae | S-W. Kim | K. Ohashi | T. Ito | T. Yamaguchi | S. Hagiwara | Michihiro Hidaka | Takuhiro Yamaguchi | Shingo Yano | Akiyoshi Takami | S. W. Kim | Toshiro Ito | K. Hatanaka | Takeshi Yamashita
[1] Y. Heike,et al. Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: a single-center retrospective analysis of 103 cases , 2013, International Journal of Hematology.
[2] A. Velardi,et al. Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] R. Bouabdallah,et al. Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft‐versus‐host disease in reduced‐intensity conditioning transplantation for hematologic diseases , 2013, Cancer.
[4] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[5] R. Suzuki,et al. Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin , 2012, International Journal of Hematology.
[6] D. Porter,et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. , 2011, Blood.
[7] H. Einsele,et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. , 2011, Blood.
[8] H. Einsele,et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. , 2009, The Lancet. Oncology.
[9] R. Gale,et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Fay,et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. , 2005, Blood.
[11] B. Storer,et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. , 2001, The New England journal of medicine.
[12] G. Ehninger,et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] A. Nagler,et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. , 2001, Experimental hematology.
[14] A. Nagler,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.